TORONTO, Ontario and CAMBRIDGE, Mass. - August 1, 2021 - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, gabve two presentations at the annual Alzheimer's Association International Conference (AAIC) held July 26-30, 2021 in Denver, USA and online.
ProMIS Chief Scientific Officer, Dr. Neil Cashman gave an oral presentation entitled: 'Selective targeting of intracellular misfolded, pathogenic TDP-43 with rationally designed intrabodies.'
Dr. Johanne Kaplan, ProMIS Chief Development Officer, presented the poster entitled: 'Conformational epitopes exposed on misfolded toxic forms of amyloid-beta, tau and alpha-synuclein directly contribute to their seeding activity.' The poster discusses conformational epitopes on misfolded proteins that represent unique targets for therapeutic antibodies.
Links to these presentation abstracts and poster below.
ProMIS Neurosciences Inc. published this content on 02 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 August 2021 13:11:06 UTC.